According to the Health Yuan announcement, the product Liconchitazumab injection from Zhuhai Lizhudan Antibiotic Technology Co., Ltd., the holding subsidiary of the company, has been included in the list of priority review varieties and has officially entered the priority review and approval process for drug marketing licenses. This drug is used to treat adult patients with moderate to severe plaque psoriasis who are suitable for systematic treatment or light therapy. As the first domestically produced and second-most advanced self-developed IL-17A/F dual-target inhibitor, leconchitazumab injection works by simultaneously blocking IL-17A and IL-17F pro-inflammatory factors.

According to the Health Yuan announcement, the product Liconchitazumab injection from Zhuhai Lizhudan Antibiotic Technology Co., Ltd., the holding subsidiary of the company, has been included in the list of priority review varieties and has officially entered the priority review and approval process for drug marketing licenses. This drug is used to treat adult patients with moderate to severe plaque psoriasis who are suitable for systematic treatment or light therapy. As the first domestically produced and second-most advanced self-developed IL-17A/F dual-target inhibitor, leconchitazumab injection works by simultaneously blocking IL-17A and IL-17F pro-inflammatory factors.